S0003701

3TC300mg+TDF300mg tabs/PAC-30


Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg, (equivalent to245mg of Tenofovir Disoproxil), film coated tablets, bottle pack of 30
Indicative Price : Upon Request

NOTE: The description below is for a standard product. It is not specific to patent status and pricing policies that may apply at country level. This information is available on request from Supply Division: Contact: supply@unicef.org

General Description:
Lamivudine 300mg + Tenofovir Disoproxil Fumarate 300mg, equivalent to 245mg of Tenofovir Disoproxil, film coated tablets, bottle pack of 30

Technical Specifications:
Each film coated tablet contains Lamivudine 300mg and Tenofovir Disoproxil fumarate 300mg which is equivalent to 245mg of Tenofovir Disoproxil.

Therapeutic class:
Lamivudine is a Nucleoside Reverse Transcriptase Inhibitor (NRTI)
Tenofovir is a Nucleotide Reverse Transcriptase Inhibitor (NtRTI)

Standard shelf life:
2 years (24 months)

Other available formulations:
The product may also be available in other formulations, pack sizes, or in combinations with other ARVs.

Guidelines for use:
For more details, please click the links listed below:

WHO treatment guidelines


and

WHO Essential Medicines Library


or your regional national guidelines

For details about paediatric dosage schemes, please click the links listed below:

WHO HIV/AIDS


WHO Generic tool for assessing paediatric ARV dosing


Indications:
Management of HIV-1 infection in adults in combination with at least two other antiretroviral drugs. By mouth (oral), PO

Storage:
Store at 25ºC (77ºF) in a tightly closed original container. Excursions permitted to 15-30ºC (59-86ºF).
Keep out of reach and sight of children.

Dispensing instructions:
Dispense in original container. Do not repack
To be taken without regard to food

Regulatory Status:
For latest updates, please click the links listed below:

List of WHO Prequalified Medicines


List of USFDA approved and tentatively approved items

Related Products